Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN) and Pharma Mar (OTCMKTS:PHMMF) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Valuation & Earnings

This table compares Imunon and Pharma Mar”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Imunon	N/A	N/A	-$18.62 million	($9.68)	-0.34
Pharma Mar	$189.23 million	N/A	$28.27 million	N/A	N/A

Pharma Mar has higher revenue and earnings than Imunon.

Volatility and Risk

Imunon has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Pharma Mar has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Imunon and Pharma Mar, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Imunon	1	1	2	0	2.25
Pharma Mar	0	0	0	0	0.00

Imunon currently has a consensus price target of $232.50, indicating a potential upside of 7,010.09%. Given Imunon’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Imunon is more favorable than Pharma Mar.

Insider and Institutional Ownership

4.5% of Imunon shares are held by institutional investors. 6.0% of Imunon shares are held by insiders. Comparatively, 1.9% of Pharma Mar shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Imunon and Pharma Mar’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Imunon	N/A	-501.10%	-166.84%
Pharma Mar	N/A	N/A	N/A

Summary

Imunon beats Pharma Mar on 6 of the 10 factors compared between the two stocks.

About Imunon

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.